Controversial 'pay-for-delay' deals drop after FTC's win in top court

WASHINGTON (Reuters) - Branded drug companies hammered out far fewer deals with generic drug makers to delay sales of cheaper medicines in the year after the Supreme Court ruled the Federal Trade Commission could legally pursue such agreements as potentially illegal.